<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728778</url>
  </required_header>
  <id_info>
    <org_study_id>V4.11-BTX-BPD</org_study_id>
    <nct_id>NCT02728778</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)</brief_title>
  <acronym>BTX-BPD</acronym>
  <official_title>Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to test whether a single application of botulinum toxin A
      into the glabellar region will lead to emotional stabilization in borderline personality
      disorder through paralysis of facial muscles/attenuation of negative emotions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Afferent feedback from facial muscles is believed to enhance emotional states (facial
      feedback theory). The facial expression of negative emotions involves facial muscles of the
      glabellar region. It has been shown that paralysis of facial muscles in the forehead using
      botulinum toxin A leads to the improvement of depressive symptoms. It is believed that the
      limited ability to express these emotions alleviates depressive symptoms. As Borderline
      personality disorder is characterized by negative emotions expressed via facial muscles in
      the forehead, it is hypothesized that BPD patients could profit from botulinum toxin
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Zanarini Scale for Borderline personality disorder (ZAN-BPD)</measure>
    <time_frame>8 weeks</time_frame>
    <description>BPD severity measure expert rating</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Borderline symptom list (BSL-23)</measure>
    <time_frame>4, 8 and 16 weeks</time_frame>
    <description>BPD severity measure self rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg-Depression-Rating-Scale (MADRS)</measure>
    <time_frame>4, 8 and 16 weeks</time_frame>
    <description>depression severity measure expert rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>4, 8 and 16 weeks</time_frame>
    <description>depression severity measure self rating</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single administration of incobotulinumtoxin A into the forehead (glabellar region); 34 U in five injection sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive four facial acupuncture treatments every two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>incobotulinumtoxin A</intervention_name>
    <description>Application of botulinum toxin A into the forehead</description>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>Application of acupuncture into the forehead</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female

          2. 18-40 years

          3. diagnosed BPD according to ICD-10 (F60.31) and SKID II

          4. stable treatment

          5. mastery of the German language

          6. effective contraception

          7. willingness to and acceptance of treatment with either botulinum toxin A or
             acupuncture

        Exclusion Criteria:

          1. Comorbid disorders of all ICD-10 groups o F0,

               -  F1 (with exception of F1x.1),

               -  F2,

               -  F3 (with exception of 32.0 and F33.0),

               -  F7 and disorders essentially defining the clinical picture from sections

               -  F4,

               -  F5,

               -  F6.

          2. Contraindication for treatment with Botulinumtoxin A according to the IMP's SmPC (e.g.
             myasthenia gravis, Lambert Eaton-syndrome or other impairments in neuromuscular
             function)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HCTC</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Clinical Trial Center HCTC GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tillmann Krüger, MD, Prof.</last_name>
    <phone>0049 511 532 2407</phone>
    <email>krueger.tillmann@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>M. Axel Wollmer, MD</last_name>
    <phone>0049 40 181887 2372</phone>
    <email>m.wollmer@asklepios.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tillmann HC Kruger, MD</last_name>
      <phone>0049-511-532-2407</phone>
      <email>borderline@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Nord-Ochsenzoll</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel Wollmer, MD</last_name>
      <phone>0049-40-181887-2337</phone>
      <email>m.wollmer@asklepios.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Tillmann Krüger</investigator_full_name>
    <investigator_title>M.D., Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

